Journal
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
Volume 7, Issue 2, Pages 92-107Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040622315620180
Keywords
liraglutide; obesity; pharmacotherapy
Categories
Ask authors/readers for more resources
There is a global obesity epidemic that will continue to be a financial burden on healthcare systems around the world. Tackling obesity through diet and exercise should always be the first intervention, but this has not proved to be effective for a large number of patients. Pharmacotherapeutic options have been limited and many previously available drugs have been withdrawn due to safety concerns. Currently, only bariatric surgery has the capability to induce both substantial and durable weight loss. This article briefly reviews the history of pharmacotherapy for obesity before focusing on the clinical trial evidence for the use of the GLP-1 agonist liraglutide as a weight loss agent and comparing its efficacy with other emerging drug therapies for obesity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available